News Neurosterix' $105m round leads the week's biotech financings Neurosterix raises $105m for its schizophrenia candidate, as Delix, VectorY, and Eli Radiopharma also add to their cash reserves.
R&D Treating mechanisms, not symptoms: ALS R&D today The ALS clinical trial landscape is characterised by a significant number of active trials and sponsors, including MediciNova's Ph3 with MN-166.
News FDA clears trial of 'vectorised' ALS antibody from VectorY VectorY has been cleared by the FDA to start human trials of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis cases.
News Changing Faces: biopharma hires from November 2022 The month of November saw a number of notable hires and personnel moves in biotech and
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.